Active Ingredient(s): Acalabrutinib
FDA Approved: * October 31, 2017
Pharm Company: * ACERTA PHARMA BV
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Calquence Overview

Acalabrutinib (rINN,[1] ACP-196) is a novel experimental anti-cancer drug and a 2nd generation Bruton's tyrosine kinase (BTK) inhibitor[2][3] developed by Acerta Pharma.[4] It is more potent and selective (fewer side-effects) than ibrutinib, the first-in-class BTK inhibitor.[2][3][5] Contents 1 Clinical and Regulatory Status 1.1 Pre-clinical 1.2 Clinical 1.3 Regulatory 2 Commercial Aspects 3 Intellectual Property 4 References Clinical and Regulatory Status Pre-clinical Relati...

Read more Calquence Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Calquence Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Calquence: (1 result)

Sorted by National Drug Code
  • 0310-0512 Calquence 100 mg Oral Capsule, Gelatin Coated by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Acalabrutinib or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 January 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.